Product information and disease descriptionPlace of product in therapyDisease description
Definition and etiology
16 evidence topics · 14 sources
Definition: FDA draft guidance on trials in treatment-resistant depression
Definition: EMA guideline on treatment resistance
Definition: regulatory definition and absence of a validated consensus definition
“A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently exist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EMA definition, contrary to the FDA one, explicitly states that the failed antidepressants can be from the same or different mechanistic classes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limitations of the FDA and EMA definitions are that they do not explicitly operationalize non‐response, and do not consider psychotherapeutic interventions, regarded as first‐line treatments for mild or moderate depression by most guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: review of expert and trial definitions for AHRQ and CMS
“We found that no consensus definition existed for TRD. The most common TRD definition for major depressive disorder required a minimum of two prior treatment failures and confirmation of prior adequate dose and duration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our systematic review found that only 17% of intervention studies enrolled samples meeting the most frequently specified criteria for TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Definition: systematic review of definitions in research and clinical practice
“In total, 155 definitions for TRD were identified in the published literature, and 48.4% of all definitions specified requirement of at least 2 treatment failures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key informant interviews indicated the concept of TRD is rarely employed in clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: Delphi consensus criteria for regulatory clinical trials
“Based on a number of guidelines and other expert documents [22–25], in this report we adopt the definition of TRD as indicating individuals who show a reduction of less than 25% in MDD severity to at least two antidepressants, and of PRD as indicating individuals who show a reduction of between 25% and <50% in MDD severity to at least one antidepressant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend (with moderate consensus, 74%) that the criteria of ‘adequate dose and duration’ is the minimal effective dosage, that is, the minimal approved dosage, administered for at least four weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: CANMAT 2023 guideline
Definition: population in the ICER assessment of psilocybin
Related concept: difficult-to-treat depression
“The group proposed that DTD be defined as "depression that continues to cause significant burden despite usual treatment efforts".” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While DTD would seem to have clinical utility, its specificity and objectivity may be insufficient to define clinical populations for regulatory trial purposes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: heterogeneous causal mechanisms
“Treatment Resistant Depression (TRD) represents a heterogeneous state with likely multiple causal mechanisms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The extent to which individuals with TRD versus treatment-responsive MDD differ in etiology or pathophysiology remains mostly obscure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both childhood adversity and stress in adulthood predict increased TRD following antidepressant treatments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: familial aggregation in a nationwide Taiwanese cohort
“TRD was defined as having experienced at least 3 distinct antidepressant treatments in the current episode, each with adequate dose and duration, based on the prescribing records.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First-degree relatives of individuals with TRD had lower incomes, more physical comorbidities, higher suicide mortality, and increased risk of developing TRD (aRR, 9.16; 95% CI, 7.21-11.63) and higher risk of other psychiatric disorders than matched control individuals, including schizophrenia (aRR, 2.36; 95% CI, 2.10-2.65), bipolar disorder (aRR, 3.74; 95% CI, 3.39-4.13), major depressive disorder (aRR, 3.65; 95% CI, 3.44-3.87), attention-deficit/hyperactivity disorders (aRR, 2.38; 95% CI, 2.20-2.58), autism spectrum disorder (aRR, 2.26; 95% CI, 1.86-2.74), anxiety disorder (aRR, 2.71; 95% CI, 2.59-2.84), and obsessive-compulsive disorder (aRR, 3.14; 95% CI, 2.70-3.66).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: heritability and polygenic associations in UK primary care cohorts
“In UKB, TRD vs healthy controls and non-TRD vs healthy controls h2SNP was comparable (0.25 [SE = 0.04] and 0.19 [SE = 0.02], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TRD vs non-TRD was positively associated with the PRS of attention deficit hyperactivity disorder, with lower socio-economic status, obesity, higher neuroticism and other unfavourable clinical characteristics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: baseline predictors in US commercial claims
“TRD patients at baseline were younger; 10.87% were between 18 and 19 years old versus 7.64% in the no‐TRD group, risk ratio (RR) = 1.42 (95% confidence interval [CI] 1.37–1.48).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3.68, fatigue had the highest RR (95% CI 3.18–4.25). TRD patients had substance use disorders, psychiatric conditions, insomnia, and pain more often at baseline than non‐TRD patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: sociodemographic characteristics
“It is established that older persons more frequently fail multiple monoamine‐based antidepressant treatments, which may be taken as evidence that TRD is more common in this subpopulation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is not established whether female sex is a risk factor for TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Socioeconomic position is a risk factor for TRD in persons receiving monoamine‐based antidepressants. For example, in the STAR*D trial, persons meeting level 2 criteria (i.e., inadequate response to two sequential antidepressant regimens) were more likely to report lower income and dependence on the public health system” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: childhood maltreatment and life stress
“There are also studies providing evidence that a reported history of childhood emotional abuse is associated with recurrent depression, persistent depression, as well as treatment resistance to antidepressants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The international Study to Predict Optimized Treatment for Depression (iSPOT‐D) reported that, amongst adults with MDD and a history of trauma between the ages of 4 and 7 years, only 15.9% achieved remission after 8 weeks of treatment with escitalopram, sertraline or venlafaxine, compared to 84.1% in individuals with no history of childhood trauma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: illness severity, episode duration, and clinical features
“Greater baseline severity is a highly replicated risk factor for TRD, and is indeed included in some frameworks as a variable in the hierarchical characterization of the condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Illness duration is also highly associated with TRD, with replicated evidence indicating that the length of a depressive episode is inversely proportional to the probability of treatment response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psychotic symptoms affect approximately 20% of adults with MDD and are highly associated with TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results from the STAR*D trial indicate that persons presenting with anxious depression exhibit attenuated antidepressant response and are more likely to develop TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote